Melissa R. Junttila

机构：ORIC Pharmaceuticals, Inc. (United States), Sunesis (United States) · ORCID：0000-0003-3538-1192

发表论文 228 篇 · 总被引 11336 次 · h-index 40

代表论文

• A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death (2024 · Blood Cancer Journal · 被引 19)
• Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models (2024 · Cancer Research · 被引 7)
• Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations (2025 · Cancer Research · 被引 5)
• 62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations (2024 · European Journal of Cancer · 被引 5)
• Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor Immunosuppression (2025 · Journal of Medicinal Chemistry · 被引 3)
• Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer (2024 · Cancer Research · 被引 2)